Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for immune-mediated diseases. Its lead program, zetomipzomib, is being advanced for autoimmune hepatitis, while earlier-stage efforts such as KZR-261 have been discontinued as the company narrows its pipeline.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaZetomipzomib is the company's main drug candidate and the focus of current development efforts.
Upfront, milestone, and contingent payments from strategic partners such as Everest.
Earlier-stage or discontinued programs and future in-licensed assets under evaluation.
Asiakkaat
Kezar does not sell approved products to end customers; its current economic counterparties are strategic partners, research vendors, and clinical development service providers. The company’s future commercial customers, if any product is approved, would be physicians, patients, and third-party payors in autoimmune and inflammatory disease markets.
Partners such as Everest that fund regional development and commercialization rights in exchange for licensed assets.
CROs, trial sites, and manufacturers that support preclinical and clinical development execution.
Potential end-market stakeholders for an approved autoimmune hepatitis therapy, if development succeeds.
Strategia
The company has shifted to a narrower pipeline strategy, discontinuing KZR-261 and terminating the PALIZADE lupus nephritis trial to concentrate resources on zetomipzomib for autoimmune hepatitis. Management is also pursuing strategic alternatives while trying to preserve cash, reduce operating complexity, and extend the runway needed for later-stage clinical development.
This is the company's lead asset and the main path to future value creation.
Stopping non-core programs reduces cash burn and concentrates resources on the highest-priority asset.
A transaction could provide financing, partnerships, or a path to value realization if standalone development is difficult.
Maantiede
Kezar is headquartered in the United States and conducts its core research and development activities there. Commercial exposure is currently limited, but the Everest collaboration gives it regional rights and development/commercialization exposure in greater China, South Korea, and select Southeast Asian countries.
Riskit
Kezar remains a high-risk development-stage biotech with no approved products and a history of operating losses, so its value depends heavily on clinical success, regulatory outcomes, and financing access. The company also faces partner dependence, patent and license risk, and the possibility that its lead asset will not achieve market acceptance even if approved.
- Clinical development failure for zetomipzomibVaikutus: KriittinenTodennäköisyys: Korkea
The lead asset must demonstrate safety and efficacy in autoimmune hepatitis to create value.
Kohdistuu: Lead program
- Dependence on Everest collaborationVaikutus: KorkeaTodennäköisyys: Korkea
Regional development and commercialization in Asia rely on a partner outside the company's control.
Kohdistuu - Ongoing operating losses and financing needVaikutus: KorkeaTodennäköisyys: Korkea
The company has no product sales and will likely need additional capital to fund trials.
Kohdistuu: Corporate liquidity
- Patent and license fragilityVaikutus: KorkeaTodennäköisyys: Kohtalainen
Loss of patent protection or breach of the Onyx license could impair commercialization rights.
Kohdistuu: Zetomipzomib IP
- Competition from larger pharmaceutical companiesVaikutus: KeskitasoTodennäköisyys: Korkea
Better-funded competitors may advance similar therapies faster or secure market share first.
Kohdistuu: Autoimmune disease pipeline
Kirjanpito
Harkinnanvaraiset erätRevenue is recognized when performance obligations are satisfied, so timing can be uneven and milestone-driven.
Vaikutus: Affects reported revenue volatility and comparability across periods
Clinical, preclinical, and manufacturing costs are generally expensed as incurred, driving operating loss timing.
Vaikutus: Directly affects quarterly burn and loss trends
The Oxford Finance facility creates cash and non-cash interest expense through accretion and amortization.
Vaikutus: Affects net loss and financing cash flow presentation
Stopping KZR-261 or PALIZADE can require write-downs of related assets or prepaid costs.
Vaikutus: May create one-time charges and reduce asset balances
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Nektar Therapeutics
NKTR · Pharmaceutical Preparations
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunotherapy medicines for autoimmune disease and cancer.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Zura Bio Ltd
ZURA · Biological Products, (No Diagnostic Substances)
Zura Bio Ltd is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-based therapies for immune-mediated diseases.
LENZ Therapeutics, Inc.
LENZ · Biological Products, (No Diagnostic Substances)
LENZ Therapeutics is a U.S.-based pre-commercial biopharmaceutical company focused on developing and commercializing VIZZ, an aceclidine-based eye drop for presbyopia.
Eledon Pharmaceuticals, Inc.
ELDN · Pharmaceutical Preparations
Tenax Therapeutics, Inc
TENX · Pharmaceutical Preparations
Päivitetty: 24.9.2026